Eli Lilly Valuation
Is LLYCL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of LLYCL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: LLYCL (CLP727465) is trading below our estimate of fair value (CLP1131699.36)
Significantly Below Fair Value: LLYCL is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LLYCL?
Key metric: As LLYCL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is LLYCL's PE Ratio? | |
|---|---|
| PE Ratio | 80.7x |
| Earnings | US$8.37b |
| Market Cap | US$678.39b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 17.3x |
| Enterprise Value/EBITDA | 42.6x |
| PEG Ratio | 2.8x |
Price to Earnings Ratio vs Peers
How does LLYCL's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 27.6x | ||
NOVO B Novo Nordisk | 33.9x | 14.4% | DKK 3.2t |
JNJ Johnson & Johnson | 25.4x | 10.6% | US$368.6b |
MRK Merck | 20.8x | 15.6% | US$246.5b |
AZN AstraZeneca | 30.3x | 18.4% | UK£156.0b |
LLYCL Eli Lilly | 80.7x | 29.2% | CL$678.4b |
Price-To-Earnings vs Peers: LLYCL is expensive based on its Price-To-Earnings Ratio (80.7x) compared to the peer average (27.6x).
Price to Earnings Ratio vs Industry
How does LLYCL's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
| 27 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 27 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: LLYCL is expensive based on its Price-To-Earnings Ratio (80.7x) compared to the Global Pharmaceuticals industry average (22.8x).
Price to Earnings Ratio vs Fair Ratio
What is LLYCL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 80.7x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate LLYCL's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CL$727,465.00 | CL$965,849.29 +32.8% | 14.6% | CL$1,216,825.00 | CL$564,606.80 | n/a | 28 |
| Nov ’25 | CL$773,580.00 | CL$966,426.73 +24.9% | 13.9% | CL$1,201,000.00 | CL$557,264.00 | n/a | 27 |
| Oct ’25 | CL$857,500.00 | CL$922,461.06 +7.6% | 13.9% | CL$1,065,710.75 | CL$537,488.90 | n/a | 25 |
| Sep ’25 | CL$857,500.00 | CL$901,855.16 +5.2% | 13.9% | CL$1,050,985.00 | CL$530,062.00 | n/a | 25 |
| Aug ’25 | n/a | CL$875,257.09 0% | 16.3% | CL$1,063,841.97 | CL$514,301.40 | n/a | 26 |
| Jul ’25 | n/a | CL$829,487.45 0% | 14.0% | CL$982,770.25 | CL$515,484.00 | n/a | 25 |
| Jun ’25 | n/a | CL$782,199.86 0% | 12.7% | CL$938,612.73 | CL$495,455.40 | n/a | 26 |
| May ’25 | n/a | CL$811,829.16 0% | 13.3% | CL$982,468.74 | CL$518,605.20 | n/a | 26 |
| Apr ’25 | n/a | CL$783,720.25 0% | 14.1% | CL$982,800.00 | CL$491,400.00 | n/a | 26 |
| Mar ’25 | n/a | CL$743,279.78 0% | 15.0% | CL$968,310.00 | CL$484,155.00 | n/a | 27 |
| Feb ’25 | n/a | CL$587,590.00 0% | 13.9% | CL$703,829.35 | CL$396,653.50 | n/a | 26 |
| Jan ’25 | n/a | CL$548,502.98 0% | 13.6% | CL$639,280.18 | CL$378,116.20 | n/a | 27 |
| Dec ’24 | n/a | CL$539,237.40 0% | 14.2% | CL$628,825.90 | CL$374,508.50 | n/a | 27 |
| Nov ’24 | n/a | CL$560,129.17 0% | 16.2% | CL$669,246.00 | CL$320,484.00 | CL$773,580.00 | 26 |
| Oct ’24 | n/a | CL$506,251.17 0% | 14.0% | CL$569,683.20 | CL$302,644.20 | CL$857,500.00 | 26 |
| Sep ’24 | n/a | CL$459,370.25 0% | 16.8% | CL$542,139.18 | CL$256,938.00 | CL$857,500.00 | 27 |
| Aug ’24 | n/a | CL$393,879.52 0% | 14.2% | CL$468,498.00 | CL$248,760.00 | n/a | 27 |
| Jul ’24 | n/a | CL$360,016.16 0% | 14.8% | CL$438,663.50 | CL$239,271.00 | n/a | 23 |
| Jun ’24 | n/a | CL$348,915.46 0% | 14.7% | CL$405,087.93 | CL$239,697.00 | n/a | 23 |
| May ’24 | n/a | CL$318,251.92 0% | 15.0% | CL$391,152.50 | CL$217,755.00 | n/a | 23 |
| Apr ’24 | n/a | CL$297,958.68 0% | 13.3% | CL$352,007.64 | CL$214,058.70 | n/a | 23 |
| Mar ’24 | n/a | CL$308,886.87 0% | 12.8% | CL$359,919.72 | CL$218,870.10 | n/a | 22 |
| Feb ’24 | n/a | CL$300,803.72 0% | 15.6% | CL$350,310.40 | CL$160,824.32 | n/a | 22 |
| Jan ’24 | n/a | CL$335,056.71 0% | 15.6% | CL$390,060.00 | CL$179,073.00 | n/a | 22 |
| Dec ’23 | n/a | CL$344,246.47 0% | 15.5% | CL$404,311.52 | CL$187,318.64 | n/a | 22 |
| Nov ’23 | n/a | CL$325,975.56 0% | 16.3% | CL$409,194.72 | CL$191,336.42 | n/a | 21 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Gilead Sciences
US$111.9b
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD
US$89.71
7D
0%
1Y
36.9%
Amgen
US$155.8b
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
AMGNCL
US$305,690.00
7D
0%
1Y
n/a
Pfizer
US$142.4b
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally.
PFE
US$27.95
7D
0%
1Y
-6.2%